Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014

Date: February 28, 2014
Pages: 114
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M7071D8D680EN
Leaflet:

Download PDF Leaflet

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014
Summary

Global Markets Direct’s, ‘Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014’, provides an overview of the Mitsubishi Tanabe Pharma Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mitsubishi Tanabe Pharma Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Mitsubishi Tanabe Pharma Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mitsubishi Tanabe Pharma Corporation’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mitsubishi Tanabe Pharma Corporation’s pipeline products
Reasons to buy
  • Evaluate Mitsubishi Tanabe Pharma Corporation’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mitsubishi Tanabe Pharma Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mitsubishi Tanabe Pharma Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mitsubishi Tanabe Pharma Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mitsubishi Tanabe Pharma Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential andScope
  • Explore the dormant and discontinued projects of Mitsubishi Tanabe Pharma Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Mitsubishi Tanabe Pharma Corporation Snapshot
Mitsubishi Tanabe Pharma Corporation Overview
Key Information
Key Facts
Mitsubishi Tanabe Pharma Corporation - Research and Development Overview
Key Therapeutic Areas
Mitsubishi Tanabe Pharma Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance
Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Drug Profiles
(canagliflozin + metformin) IR
Product Description
Mechanism of Action
R&D Progress
telaprevir
Product Description
Mechanism of Action
R&D Progress
teneligliptin
Product Description
Mechanism of Action
R&D Progress
(canagliflozin + metformin) XR
Product Description
Mechanism of Action
R&D Progress
bepotastine besylate
Product Description
Mechanism of Action
R&D Progress
colestilan chloride
Product Description
Mechanism of Action
R&D Progress
edaravone
Product Description
Mechanism of Action
R&D Progress
encenicline
Product Description
Mechanism of Action
R&D Progress
fingolimod hydrochloride
Product Description
Mechanism of Action
R&D Progress
infliximab
Product Description
Mechanism of Action
R&D Progress
cariprazine
Product Description
Mechanism of Action
R&D Progress
CYR-101
Product Description
Mechanism of Action
R&D Progress
M-5200
Product Description
Mechanism of Action
R&D Progress
masilukast
Product Description
Mechanism of Action
R&D Progress
MT-1303
Product Description
Mechanism of Action
R&D Progress
MT-3995
Product Description
Mechanism of Action
R&D Progress
nalfurafine hydrochloride
Product Description
Mechanism of Action
R&D Progress
osemozotan
Product Description
Mechanism of Action
R&D Progress
MT-4580
Product Description
Mechanism of Action
R&D Progress
GB-1057
Product Description
Mechanism of Action
R&D Progress
MP-124
Product Description
Mechanism of Action
R&D Progress
MP-157
Product Description
Mechanism of Action
R&D Progress
TT-138
Product Description
Mechanism of Action
R&D Progress
WF-516
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Aurora A Kinase for Solid Tumor
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit DPP-IV for Hyperglycemia
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit GSK-3 Beta for Alzheimers Disease
Product Description
Mechanism of Action
R&D Progress
Small Molecule To Inhibit Sodium and hERG Channel For Ischemic Stroke
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Sodium Channels for Ischemic Stroke
Product Description
Mechanism of Action
R&D Progress
TA-3404
Product Description
Mechanism of Action
R&D Progress
Y-320
Product Description
Mechanism of Action
R&D Progress
Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates
Mitsubishi Tanabe Pharma Corporation - Dormant Projects
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
masilukast
sofigatran
activated charcoal
AV-412
caldaret
coleneuramide
colestilan chloride
DEZ-001
edaravone
immune globulin intravenous
marimastat
masilukast
MP-136
MP-435
MT-7716
netoglitazone
TA-5493
TA-5538
TA-6666
Y-700
Mitsubishi Tanabe Pharma Corporation - Company Statement
Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Mitsubishi Tanabe Pharma Corporation, Key Information
Mitsubishi Tanabe Pharma Corporation, Key Facts
Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2014
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2014
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014
Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2014
Mitsubishi Tanabe Pharma Corporation - Filing rejected/Withdrawn, 2014
Mitsubishi Tanabe Pharma Corporation - Phase III, 2014
Mitsubishi Tanabe Pharma Corporation - Phase II, 2014
Mitsubishi Tanabe Pharma Corporation - Phase I, 2014
Mitsubishi Tanabe Pharma Corporation - Preclinical, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2014
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates, 2014
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2014
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2014
Mitsubishi Tanabe Pharma Corporation, Other Locations
Mitsubishi Tanabe Pharma Corporation, Subsidiaries

LIST OF FIGURES

Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Indication, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2014
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Target, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Route of Administration, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Molecule Type, 2014
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014

Ask Your Question

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: